Supernus Pharmaceuticals (SUPN) Jumps On Merger Terms, Is The Stock Still Cheap?

Merger terms reshape the outlook for Supernus Pharmaceuticals stock

Supernus Pharmaceuticals (SUPN) is in focus after Indivior Pharmaceuticals agreed on a US$3.6b all stock merger of equals, with Supernus investors set to receive Indivior shares based on a fixed exchange ratio.

See our latest analysis for Supernus Pharmaceuticals.

The merger announcement comes as Supernus Pharmaceuticals’ share price has moved sharply on the day with an 8.46% 1 day share price return, yet its year to date share price return is down 5.17% while the 5 year total shareholder return sits at 91.24%. This suggests shorter term momentum has cooled compared with a stronger long term record.

If this merger has you reassessing the sector, it could be a useful moment to broaden your watchlist with 42 healthcare AI stocks.

Supernus Pharmaceuticals now trades at a sizeable discount to both intrinsic value estimates and analyst targets after the merger pop. Is the market fairly pricing risks around recent losses and updated guidance, or is it leaning too hard on caution?

Most Popular Narrative: 25.3% Undervalued

On the latest close, Supernus Pharmaceuticals shares at $46.91 sit well below the most followed narrative fair value of $62.83. This valuation assumes meaningful progress on growth and profitability over the rest of the decade.

Expanding patient pool for core products, Qelbree and GOCOVRI, driven by increased prevalence and diagnosis of CNS disorders, as well as broader healthcare access, especially among Medicare patients, as seen with GOCOVRI’s prescription growth, is likely to sustain robust top-line revenue growth. Commercial infrastructure and recent launch of ONAPGO position Supernus to capture further market share in Parkinson’s disease, benefiting from demographic aging and rising CNS disease burden, which should materially boost revenue and improve gross margins as fixed costs are leveraged.

Read the complete narrative.

Want to understand why this valuation sits well above today’s price? The narrative leans on faster revenue growth, higher margins, and a richer future earnings multiple. Curious how those ingredients combine into that $62.83 figure and what would need to go right for Supernus Pharmaceuticals to get there?

Result: Fair Value of $62.83 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, Supernus Pharmaceuticals still carries key risks, including heavy dependence on a few CNS products and rising R&D and SG&A costs that keep GAAP operating losses in focus.

Find out about the key risks to this Supernus Pharmaceuticals narrative.

Next Steps

With sentiment on Supernus Pharmaceuticals clearly mixed, this is a good time to move quickly, review the underlying numbers, and form your own view by checking the 4 key rewards

Looking for more investment ideas beyond Supernus Pharmaceuticals?

If this Supernus Pharmaceuticals merger has sharpened your focus, do not stop here. Use the Simply Wall St screener to quickly surface fresh, data driven ideas.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com